|
Market Closed -
Other stock markets
|
After hours 08:00:00 pm | |||
| 25.58 USD | +1.71% |
|
25.58 | -0.02% |
| Jan. 14 | Sanofi sees near-term weakness in US vaccines sales due to antivax rhetoric | RE |
| Jan. 14 | Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030 | RE |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.93 | 10 | 12.87 | 1.55 | 4.64 | |||||
Return on Total Capital | 5.71 | 15.01 | 19.18 | 2.19 | 6.37 | |||||
Return On Equity % | 11.06 | 31.87 | 36.22 | 2.35 | 9.06 | |||||
Return on Common Equity | 11.06 | 31.92 | 36.29 | 2.31 | 9.05 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 79.54 | 62.28 | 66.02 | 58.99 | 74.19 | |||||
SG&A Margin | 25.99 | 11.77 | 12.16 | 23.65 | 23.21 | |||||
EBITDA Margin % | 35.52 | 39.3 | 43.88 | 19.69 | 36.65 | |||||
EBITA Margin % | 32.37 | 37.58 | 42.46 | 17.08 | 33.97 | |||||
EBIT Margin % | 24.17 | 33.02 | 38.87 | 8.99 | 25.66 | |||||
Income From Continuing Operations Margin % | 16.75 | 27.63 | 31.3 | 3.71 | 12.65 | |||||
Net Income Margin % | 22.95 | 27.04 | 31.27 | 3.62 | 12.62 | |||||
Net Avail. For Common Margin % | 16.67 | 27.57 | 31.26 | 3.65 | 12.6 | |||||
Normalized Net Income Margin | 17.24 | 21.41 | 25.02 | 7.51 | 13.72 | |||||
Levered Free Cash Flow Margin | 25.05 | 37.96 | 24.87 | 1.75 | 20.08 | |||||
Unlevered Free Cash Flow Margin | 27.22 | 38.95 | 25.65 | 4.11 | 23.12 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.26 | 0.48 | 0.53 | 0.28 | 0.29 | |||||
Fixed Assets Turnover | 2.84 | 4.95 | 5.42 | 2.84 | 2.99 | |||||
Receivables Turnover (Average Receivables) | 5.7 | 8.38 | 8.95 | 5.29 | 5.53 | |||||
Inventory Turnover (Average Inventory) | 1.13 | 3.59 | 3.78 | 2.5 | 1.56 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.35 | 1.4 | 1.22 | 0.91 | 1.17 | |||||
Quick Ratio | 0.9 | 1.1 | 0.88 | 0.58 | 0.82 | |||||
Operating Cash Flow to Current Liabilities | 0.56 | 0.76 | 0.69 | 0.18 | 0.3 | |||||
Days Sales Outstanding (Average Receivables) | 64.2 | 43.54 | 40.8 | 69.04 | 66.23 | |||||
Days Outstanding Inventory (Average Inventory) | 322.59 | 101.66 | 96.56 | 145.84 | 234.49 | |||||
Average Days Payable Outstanding | 157.02 | 56.77 | 66.45 | 97.92 | 132.23 | |||||
Cash Conversion Cycle (Average Days) | 229.76 | 88.42 | 70.91 | 116.96 | 168.49 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 65.02 | 53.44 | 41.05 | 84.37 | 76.18 | |||||
Total Debt / Total Capital | 39.4 | 34.83 | 29.1 | 45.76 | 43.24 | |||||
LT Debt/Equity | 60.26 | 49.97 | 37.33 | 72.17 | 67.9 | |||||
Long-Term Debt / Total Capital | 36.51 | 32.56 | 26.46 | 39.14 | 38.54 | |||||
Total Liabilities / Total Assets | 58.84 | 57.32 | 51.36 | 60.58 | 58.53 | |||||
EBIT / Interest Expense | 6.99 | 20.79 | 31.5 | 2.38 | 5.28 | |||||
EBITDA / Interest Expense | 10.81 | 25.44 | 36.54 | 5.79 | 7.93 | |||||
(EBITDA - Capex) / Interest Expense | 9.25 | 23.34 | 33.93 | 4.03 | 6.98 | |||||
Total Debt / EBITDA | 2.64 | 1.26 | 0.87 | 5.89 | 2.75 | |||||
Net Debt / EBITDA | 1.85 | 0.31 | 0.37 | 4.89 | 1.92 | |||||
Total Debt / (EBITDA - Capex) | 3.08 | 1.37 | 0.94 | 8.47 | 3.12 | |||||
Net Debt / (EBITDA - Capex) | 2.17 | 0.34 | 0.4 | 7.04 | 2.17 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 1.79 | 95.16 | 23.43 | -41.7 | 6.84 | |||||
Gross Profit, 1 Yr. Growth % | 0.62 | 52.11 | 30.89 | -47.9 | 13.03 | |||||
EBITDA, 1 Yr. Growth % | 5.33 | 123.2 | 37.21 | -73.84 | 24.22 | |||||
EBITA, 1 Yr. Growth % | 5.64 | 135 | 38.87 | -76.55 | 25.3 | |||||
EBIT, 1 Yr. Growth % | 20.89 | 178.19 | 44.54 | -86.51 | 30.45 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -35.39 | 236.9 | 39.82 | -93.08 | 270.5 | |||||
Net Income, 1 Yr. Growth % | -40.91 | 139.97 | 42.74 | -93.25 | 279 | |||||
Normalized Net Income, 1 Yr. Growth % | 36.68 | 168.88 | 42.98 | -82.5 | 5.57 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -35.06 | 233.05 | 39.19 | -93.24 | 281.08 | |||||
Accounts Receivable, 1 Yr. Growth % | 17.1 | 45.06 | -4.59 | 2.05 | -0.89 | |||||
Inventory, 1 Yr. Growth % | 13.84 | 12.96 | -0.86 | 13.45 | 6.5 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 7.26 | 17.12 | 8.77 | 13.43 | -5.41 | |||||
Total Assets, 1 Yr. Growth % | -7.97 | 17.67 | 8.67 | 14.86 | -5.79 | |||||
Tangible Book Value, 1 Yr. Growth % | -22.1 | -119.43 | -67.83 | -4.87K | -18.17 | |||||
Common Equity, 1 Yr. Growth % | 0.18 | 22.08 | 23.91 | -6.95 | -0.91 | |||||
Cash From Operations, 1 Yr. Growth % | 14.42 | 126.2 | -10.17 | -70.27 | 46.48 | |||||
Capital Expenditures, 1 Yr. Growth % | 8.69 | 21.79 | 19.37 | 20.74 | -25.54 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -24.66 | 189.11 | -19.34 | -95.9 | 129.78 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -23.55 | 173.46 | -18.95 | -90.65 | 111.91 | |||||
Dividend Per Share, 1 Yr. Growth % | 5.56 | 2.63 | 2.56 | 2.5 | 2.44 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 1.32 | 40.97 | 55.2 | -15.17 | -20.7 | |||||
Gross Profit, 2 Yr. CAGR % | 2.14 | 23.75 | 41.1 | -17.42 | -16.11 | |||||
EBITDA, 2 Yr. CAGR % | 5.14 | 51.84 | 74.52 | -40.09 | -27.9 | |||||
EBITA, 2 Yr. CAGR % | 5.92 | 55.88 | 80.07 | -42.93 | -29.47 | |||||
EBIT, 2 Yr. CAGR % | 17.35 | 81.58 | 99.57 | -55.85 | -35.98 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 34.85 | 44.63 | 117.04 | -68.89 | -49.36 | |||||
Net Income, 2 Yr. CAGR % | -7.15 | 17.11 | 85.07 | -68.95 | -49.4 | |||||
Normalized Net Income, 2 Yr. CAGR % | 23.54 | 82.62 | 94.92 | -50.06 | -41.03 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 39.21 | 44.32 | 115.3 | -69.32 | -49.23 | |||||
Accounts Receivable, 2 Yr. CAGR % | -0.59 | 30.19 | 17.65 | -1.32 | 2.31 | |||||
Inventory, 2 Yr. CAGR % | 3.52 | 13.21 | 5.82 | 6.05 | 9.92 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 6.89 | 11.48 | 12.87 | 11.08 | 3.58 | |||||
Total Assets, 2 Yr. CAGR % | -1.64 | 4.06 | 13.08 | 11.72 | 4.02 | |||||
Tangible Book Value, 2 Yr. CAGR % | -23.39 | -61.3 | -75 | 291.65 | 524.6 | |||||
Common Equity, 2 Yr. CAGR % | -0.12 | 10.59 | 22.99 | 7.38 | -3.98 | |||||
Cash From Operations, 2 Yr. CAGR % | -4.6 | 60.88 | 42.55 | -48.32 | -34.01 | |||||
Capital Expenditures, 2 Yr. CAGR % | 6.54 | 15.11 | 20.57 | 20.05 | -5.19 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 185.26 | 47.45 | 52.29 | -81.81 | -29.19 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 132.34 | 44.45 | 48.51 | -72.48 | -25.16 | |||||
Dividend Per Share, 2 Yr. CAGR % | 5.72 | 4.08 | 2.6 | 2.53 | 2.47 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -7.26 | 25.81 | 34.86 | 11.99 | -7.84 | |||||
Gross Profit, 3 Yr. CAGR % | -7.21 | 16.58 | 26.07 | 1.23 | -2.29 | |||||
EBITDA, 3 Yr. CAGR % | -10.68 | 33.37 | 47.01 | -7.29 | -10.09 | |||||
EBITA, 3 Yr. CAGR % | -11.35 | 36.19 | 50.21 | -8.72 | -11.02 | |||||
EBIT, 3 Yr. CAGR % | -11.7 | 53.97 | 68.56 | -18.71 | -15.41 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -30.98 | 79.84 | 43.01 | -31.18 | -28.96 | |||||
Net Income, 3 Yr. CAGR % | -23.3 | 25.37 | 25.09 | -38.61 | -28.51 | |||||
Normalized Net Income, 3 Yr. CAGR % | -7.51 | 54.32 | 68.81 | -12.71 | -20.87 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -29.35 | 83.13 | 42.59 | -32.06 | -28.94 | |||||
Accounts Receivable, 3 Yr. CAGR % | -1.19 | 12.67 | 17.38 | 12.2 | -0.05 | |||||
Inventory, 3 Yr. CAGR % | 2.02 | 6.46 | 8.31 | 8.31 | 6.2 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 3.32 | 9.81 | 10.57 | 13.05 | 5.29 | |||||
Total Assets, 3 Yr. CAGR % | -3.53 | 4.41 | 5.57 | 13.67 | 5.55 | |||||
Tangible Book Value, 3 Yr. CAGR % | -23.75 | -51.68 | -63.61 | 43.9 | 132.4 | |||||
Common Equity, 3 Yr. CAGR % | -3.91 | 6.79 | 14.86 | 12.07 | 4.54 | |||||
Cash From Operations, 3 Yr. CAGR % | -5.01 | 27.21 | 32.48 | -15.47 | -26.87 | |||||
Capital Expenditures, 3 Yr. CAGR % | 4.81 | 10.97 | 16.51 | 20.63 | 2.38 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -7.55 | 188.1 | 20.7 | -54.34 | -25.53 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -6.78 | 146.54 | 19.25 | -40.93 | -22.62 | |||||
Dividend Per Share, 3 Yr. CAGR % | 5.9 | 4.68 | 3.57 | 2.57 | 2.5 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -3.02 | 9 | 13.81 | 7.46 | 9.24 | |||||
Gross Profit, 5 Yr. CAGR % | -3.33 | 4.36 | 9.68 | 1.55 | 7.39 | |||||
EBITDA, 5 Yr. CAGR % | -4.59 | 10.21 | 16.08 | -3.08 | 10.97 | |||||
EBITA, 5 Yr. CAGR % | -4.99 | 10.97 | 16.96 | -3.74 | 11.45 | |||||
EBIT, 5 Yr. CAGR % | -5.99 | 13.75 | 21.53 | -6.49 | 14.93 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 0.13 | 25.44 | 8.02 | -10.86 | -5.6 | |||||
Net Income, 5 Yr. CAGR % | 6.68 | 24.96 | 8.04 | -28.26 | -12.91 | |||||
Normalized Net Income, 5 Yr. CAGR % | -5.07 | 13.75 | 22.41 | -1.48 | 10.84 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 2.23 | 27.42 | 9.24 | -10.38 | -5.66 | |||||
Accounts Receivable, 5 Yr. CAGR % | -0.61 | 6.89 | 5.9 | 6.85 | 11.1 | |||||
Inventory, 5 Yr. CAGR % | 1.38 | 5.96 | 3.46 | 6.3 | 8.95 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 2.13 | 5.88 | 6.81 | 10.31 | 7.72 | |||||
Total Assets, 5 Yr. CAGR % | -1.62 | 1.12 | 2.8 | 7.28 | 4.95 | |||||
Tangible Book Value, 5 Yr. CAGR % | -9.13 | -43.06 | -51.29 | 11.59 | 13.45 | |||||
Common Equity, 5 Yr. CAGR % | -0.45 | 5.34 | 6.06 | 7.03 | 6.92 | |||||
Cash From Operations, 5 Yr. CAGR % | -0.39 | 15.01 | 11.74 | -11.28 | 0.25 | |||||
Capital Expenditures, 5 Yr. CAGR % | 10.02 | 8.26 | 10.59 | 14.51 | 7.29 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -5.32 | 18.96 | 13.44 | -4.51 | -2.08 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -4.75 | 18.25 | 12.82 | 2.62 | -0.62 | |||||
Dividend Per Share, 5 Yr. CAGR % | 6.3 | 5.39 | 4.56 | 3.82 | 3.13 |
- Stock Market
- Equities
- PFE Stock
- Financials Pfizer Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















